Replies to post #44520 on Biotech Values

[spartex]

DNDN survey: You're right, your statement isn't misleading; it just highlights that 1/3 of those who voted feel that the FDA will most likely vote "approvable" for Provenge. Assuming this poll truly does reflect reality of the upcoming FDA decision, it would indicate that people buying DNDN stock at current prices need to realize there is still risk of the price dropping, regardless of which way the FDA goes. Those of us getting in during the $3.7 to 5's or even a bit higher are in a much better position to weather any storms from the May FDA decision. Which is why I find it critical to establish ones biotech position during the lows of a stock -- if you can patiently wait for the opportunity.

[gofishmarko]

The problem I find with the survey is it doesn't have an option for the outcome that I consider most likely , i.e. immediate marketing approval conditioned on the completion of 02b for regular approval ( in effect : accelerated approval ).

Anyone who thought this was the likely outcome would probably have chosen the "approvable" option in the survey , since that was the only answer that listed completion of 02b as a condition.